Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTNQCE)

Drug Name

L-betagamma-meATP Drug Info

Synonyms

UFZTZBNSLXELAL-IOSLPCCCSA-N; AMP-PCP; beta,gamma-Methylene ATP; phosphomethylphosphonic acid adenylate ester; CHEMBL133463; CHEBI:40532; 5'-O-(hydroxy{[hydroxy(phosphonomethyl)phosphoryl]oxy}phosphoryl)adenosine; ADENOSINE 5'-[BETA,GAMMA-METHYLENE]TRIPHOSPHATE; ADENOSINE-5'-[BETA, GAMMA-METHYLENE]TRIPHOSPHATE; 3469-78-1; adenosine 5'-beta,gamma-mu-methylenetriphosphate; ({[({[(2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}methyl)phosphonic acid; AMPPCP; betagamma-methylene-adenosine 5'-triphosphate; Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1] , [2]

Cross-matching ID

PubChem CID: 91532
ChEBI ID: CHEBI:40532
CAS Number: CAS 3469-78-1
TTD Drug ID: DMTNQCE

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Investigative Drug(s)

Approved Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting P2X purinoceptor 1 (P2RX1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
BzATP	DM37GYA	Discovery agent	N.A.	Investigative	[3]
TNP-ATP	DMVZY0X	Discovery agent	N.A.	Investigative	[4]
MRS 2219	DM7IK68	Discovery agent	N.A.	Investigative	[5]
NF023	DMJ4GO9	Discovery agent	N.A.	Investigative	[3]
NF449	DM816Z2	Discovery agent	N.A.	Investigative	[6]
Ip5I	DMB2YXN	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Drug(s) Targeting Insulin receptor (INSR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Meglitinides	DM1OFHN	Type-2 diabetes	5A11	Approved	[7]
Human neutral insulin	DMA5OBU	Diabetic complication	5A2Y	Approved	[8]
Insulin Lyspro recombinant	DM5XHVR	Diabetic complication	5A2Y	Approved	[8]
Insulin, porcine	DMO95XI	Diabetic complication	5A2Y	Approved	[9]
Insulin recombinant	DMYVP5G	Diabetic complication	5A2Y	Approved	[8]
Metformin arginine-hemisuccinimide	DMTPAM3	Type-2 diabetes	5A11	Approved	[10]
Insulin-lispro	DM4O90W	Diabetic complication	5A2Y	Approved	[11]
Insulin-glulisine	DMQI0FU	Diabetic complication	5A2Y	Approved	[12]
Ryzodeq	DMOFP18	Type-2 diabetes	5A11	Approved	[13]
NN5401	DM0QV27	Diabetic complication	5A2Y	Phase 3	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Insulin receptor (INSR)	TTCBFJO	INSR_HUMAN	Inhibitor	[1]
P2X purinoceptor 1 (P2RX1)	TTJW7B3	P2RX1_HUMAN	Agonist	[3]
Pyridoxal kinase (PDXK)	TTXI3KF	PDXK_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4236).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 478).
4	Trinitrophenyl-substituted nucleotides are potent antagonists selective for P2X1, P2X3, and heteromeric P2X2/3 receptors. Mol Pharmacol. 1998 Jun;53(6):969-73.
5	A pyridoxine cyclic phosphate and its 6-azoaryl derivative selectively potentiate and antagonize activation of P2X1 receptors. J Med Chem. 1998 Jun 18;41(13):2201-6.
6	Structure-activity relationships of analogues of NF449 confirm NF449 as the most potent and selective known P2X1 receptor antagonist. Eur J Med Chem. 2004 Apr;39(4):345-57.
7	New drugs for type 2 diabetes mellitus: what is their place in therapy Drugs. 2008;68(15):2131-62.
8	Knockouts model the 100 best-selling drugs--will they model the next 100 Nat Rev Drug Discov. 2003 Jan;2(1):38-51.
9	Acidic residues on the N-terminus of proinsulin C-Peptide are important for the folding of insulin precursor. J Biochem. 2002 Jun;131(6):855-9.
10	Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem Pharmacol. 2004 Jun 1;67(11):2081-91.
11	Hope for insulin mimetic oral antidiabetic drugs. Eur J Endocrinol. 1999 Dec;141(6):561-2.
12	Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009;69(8):1035-57.
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1800).